IDXX
IDEXX Laboratories Inc
$
697.000
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
698.135
Open
697.760
VWAP
697.27
Vol
21.97K
Mkt Cap
56.01B
Low
694.080
Amount
15.32M
EV/EBITDA(TTM)
39.26
Total Shares
82.59M
EV
56.79B
EV/OCF(TTM)
52.19
P/S(TTM)
13.72
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.07B
+12.14%
2.936
+12.04%
1.10B
+9.84%
3.380
+14.19%
1.19B
+7.45%
3.922
+8.03%
Estimates Revision
The market is revising Upward the revenue expectations for IDEXX Laboratories, Inc. (IDXX) for FY2025, with the revenue forecasts being adjusted by 0.06% over the past three months. During the same period, the stock price has changed by 6.58%.
Revenue Estimates for FY2025
Revise Upward
+0.06%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+1.52%
In Past 3 Month
Stock Price
Go Up
+6.58%
In Past 3 Month
10 Analyst Rating
3.86% Upside
Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is 723.89 USD with a low forecast of 640.00 USD and a high forecast of 785.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
4 Hold
0 Sell
Moderate Buy
3.86% Upside
Current: 697.000
Low
640.00
Averages
723.89
High
785.00
3.86% Upside
Current: 697.000
Low
640.00
Averages
723.89
High
785.00
Piper Sandler
Neutral
maintain
$700 -> $775
2025-11-10
New
Reason
Piper Sandler
Price Target
$700 -> $775
2025-11-10
New
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Idexx Laboratories to $775 from $700 following quarterly results. The firm keeps a Neutral rating on the shares.
BTIG
Buy
maintain
$785 -> $830
2025-11-04
Reason
BTIG
Price Target
$785 -> $830
2025-11-04
maintain
Buy
Reason
BTIG raised the firm's price target on Idexx Laboratories to $830 from $785 and keeps a Buy rating on the shares after its "strong" Q3 earnings beat. The growth was broad based and the quality of the beat was high, the analyst tells investors in a research note.
UBS
Neutral
maintain
$710 -> $750
2025-11-04
Reason
UBS
Price Target
$710 -> $750
2025-11-04
maintain
Neutral
Reason
UBS raised the firm's price target on Idexx Laboratories to $750 from $710 and keeps a Neutral rating on the shares. The macro is showing signs of life, the analyst tells investors in a research note.
Morgan Stanley
Overweight
maintain
$765 -> $805
2025-11-04
Reason
Morgan Stanley
Price Target
$765 -> $805
2025-11-04
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Idexx Laboratories to $805 from $765 and keeps an Overweight rating on the shares. Following a "strong" Q3 report and lifted 2025 guidance, the firm came away " incrementally constructive," the analyst tells investors. Following the report, the firm has "greater conviction in its growth prospects with one of the most compelling innovation pipelines in the company's history," the analyst added.
Stifel
Jonathan Block
Buy
upgrade
$700 -> $775
2025-11-03
Reason
Stifel
Jonathan Block
Price Target
$700 -> $775
2025-11-03
upgrade
Buy
Reason
Stifel analyst Jonathan Block raised the firm's price target on Idexx Laboratories to $775 from $700 and keeps a Buy rating on the shares. The firm says that its upgrade thesis from last week was that visits get modestly better, a soft landing occurs with price, and the "IDEXX premium" continues to strengthen. This should allow CAG Dx recurring revenue growth to accelerate in 2026/2027, which Stifel believes will support the stock's multiple at current levels. These variables all played out in the quarter as visits and the "premium" improved, and price has proved somewhat durable, the firm argues.
Leerink
Outperform
maintain
$745 -> $785
2025-11-03
Reason
Leerink
Price Target
$745 -> $785
2025-11-03
maintain
Outperform
Reason
Leerink raised the firm's price target on Idexx Laboratories to $785 from $745 and keeps an Outperform rating on the shares. The firm notes the company's Q3 print and guide increase were impressive, serving as another reminder of its best-in-class competitive positioning and amenable end markets. Idexx posted strong organic growth in the U.S. and International CAG recurring Dx businesses, underscoring the size of the current diagnostic market opportunity and the company's ability to execute against it. Idexx clearly continues to execute well, using the growth levers that it has at its disposal to drive results, says Leerink.
See All Ratings
Valuation Metrics
The current forward P/E ratio for IDEXX Laboratories Inc (IDXX.O) is 50.47, compared to its 5-year average forward P/E of 50.87. For a more detailed relative valuation and DCF analysis to assess IDEXX Laboratories Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
50.87
Current PE
50.47
Overvalued PE
63.19
Undervalued PE
38.55
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
35.56
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
44.09
Undervalued EV/EBITDA
27.03
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
18.44
Current PS
701.48
Overvalued PS
87.70
Undervalued PS
-50.81
Financials
Annual
Quarterly
FY2025Q3
YoY :
+13.29%
1.11B
Total Revenue
FY2025Q3
YoY :
+16.77%
354.85M
Operating Profit
FY2025Q3
YoY :
+17.94%
274.61M
Net Income after Tax
FY2025Q3
YoY :
+21.43%
3.40
EPS - Diluted
FY2025Q3
YoY :
+86.40%
357.88M
Free Cash Flow
FY2025Q3
YoY :
+1.19%
61.83
Gross Profit Margin - %
FY2025Q3
YoY :
+9.46%
22.56
FCF Margin - %
FY2025Q3
YoY :
+4.11%
24.85
Net Margin - %
FY2025Q3
YoY :
+13.20%
42.02
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
6.6M
USD
1
3-6
Months
34.3M
USD
7
6-9
Months
3.2M
USD
4
0-12
Months
6.0M
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 764.05% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
25.2K
Volume
3
0-12
Months
59.5K
Volume
8
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
14
674.2K
Volume
Months
0-12
12
78.0K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
24.0K
USD
3
3-6
Months
40.0K
USD
5
6-9
Months
191.0K
USD
3
0-12
Months
0.0
USD
0
Bought
0-3
2
16.0K
USD
Months
3-6
0
0.0
USD
Months
6-9
16
311.0K
USD
Months
0-12
1
8.0K
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
6.6M
USD
1
3-6
Months
34.3M
USD
7
6-9
Months
3.2M
USD
4
0-12
Months
6.0M
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
IDXX News & Events
Events Timeline
2025-11-03 (ET)
2025-11-03
09:55:01
Significant Early Gainers in Liquid Options on November 3rd
2025-11-03
06:34:32
Idexx Laboratories increases FY25 EPS forecast to $12.81-$13.01, up from $12.40-$12.76
2025-11-03
06:31:29
Idexx Laboratories Announces Q3 Earnings Per Share of $3.40, Exceeding Consensus Estimate of $3.14
Sign Up For More Events
Sign Up For More Events
News
4.5
11-12NASDAQ.COMSignificant ETF Withdrawals for SOXS and LCG
9.5
11-11NASDAQ.COMVCYT Shares Rise Following Strong Q3 Earnings and Revenue, 2025 Outlook Improved
6.5
11-04BenzingaMeta Platforms, S&P Global, and a Healthcare Stock Featured in CNBC's 'Final Trades'
Sign Up For More News
People Also Watch
COF
Capital One Financial Corp
211.675
USD
-2.36%
ERIC
Telefonaktiebolaget LM Ericsson
9.730
USD
-1.22%
NVS
Novartis AG
132.090
USD
+0.14%
LCID
Lucid Group Inc
14.620
USD
-3.63%
ZS
Zscaler Inc
299.750
USD
-2.87%
ABT
Abbott Laboratories
129.790
USD
+0.41%
PM
Philip Morris International Inc
154.320
USD
-0.53%
LIN
Linde PLC
426.590
USD
-0.48%
SHEL
Shell PLC
74.870
USD
-1.38%
ISRG
Intuitive Surgical Inc
555.720
USD
-1.73%
FAQ
What is IDEXX Laboratories Inc (IDXX) stock price today?
The current price of IDXX is 697 USD — it has decreased -0.64 % in the last trading day.
What is IDEXX Laboratories Inc (IDXX)'s business?
What is the price predicton of IDXX Stock?
What is IDEXX Laboratories Inc (IDXX)'s revenue for the last quarter?
What is IDEXX Laboratories Inc (IDXX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for IDEXX Laboratories Inc (IDXX)'s fundamentals?
How many employees does IDEXX Laboratories Inc (IDXX). have?